labetalol has been researched along with Thrombopenia in 1 studies
Labetalol: A salicylamide derivative that is a non-cardioselective blocker of BETA-ADRENERGIC RECEPTORS and ALPHA-1 ADRENERGIC RECEPTORS.
labetalol : A diastereoisomeric mixture of approximately equal amounts of all four possible stereoisomers ((R,S)-labetolol, (S,R)-labetolol, (S,S)-labetalol and (R,R)-labetalol). It is an adrenergic antagonist used to treat high blood pressure.
2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide : A member of the class of benzamides that is benzamide substituted by a hydroxy group at position 2 and by a 1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl group at position 5.
Excerpt | Relevance | Reference |
---|---|---|
"Labetalol was discontinued on day 8, but no additional significant rise occurred." | 1.33 | Suspected beta-antagonist-induced thrombocytopenia. ( Jenkins, JK; Stamm, PL; Vigrass, HG, 2005) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Stamm, PL | 1 |
Jenkins, JK | 1 |
Vigrass, HG | 1 |
1 other study available for labetalol and Thrombopenia
Article | Year |
---|---|
Suspected beta-antagonist-induced thrombocytopenia.
Topics: Adrenergic beta-Antagonists; Adult; Female; Humans; Labetalol; Lupus Erythematosus, Systemic; Nadolo | 2005 |